Clinical Trial Update: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts [Phase 2]

View source ↗

Summary

A Phase II trial is evaluating a combination regimen of cladribine and low-dose cytarabine with venetoclax, alternating with azacitidine and venetoclax, in pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Cladribine (cladribine)
• Low-dose cytarabine (Cytarabine (low-dose))
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia | Phase 2 | Status: RECRUITING